A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2027

Conditions
R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

CNTY-101

CNTY-101 cells for intravenous (IV) infusion

BIOLOGICAL

IL-2

IL-2 subcutaneous (SQ) injection

DRUG

Lymphodepleting Chemotherapy

LDC as prespecified in the protocol.

Trial Locations (16)

20007

Medstar Georgetown University Hospital, Washington D.C.

21201

University of Maryland Medical Center, Baltimore

23502

Virginia Oncology Associates, Norfolk

28204

Levine Cancer Institute, Charlotte

37232

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky - Markey Cancer Center, Lexington

45229

University of Cincinnati Medical Center, Cincinnati

45236

Oncology Hematology Care, Inc-Kenwood, Cincinnati

48202

Henry Ford Hospital, Detroit

49503

Corewell Health, Grand Rapids

75390

UT Southwestern, Dallas

77030

Houston Methodist Research Institute, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

90033

University of Southern California - Norris Comprehensive Cancer Center, Los Angeles

92093

University of California San Diego, Moores Cancer Center, San Diego

98104

Swedish Cancer Institute, Seattle

Sponsors
All Listed Sponsors
lead

Century Therapeutics, Inc.

INDUSTRY